ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab

Meral Uner, Bassam Alhasson, Jagdeep Obhrai, Serena M. Bagnasco

Research output: Contribution to journalArticlepeer-review


Cancer immunotherapy is rapidly changing the treatment paradigm in oncology, and immune checkpoint inhibitors (ICPIs) have been used successfully in a variety of cancer types. Specific side effects termed immune-related adverse events (irAEs) have now been described in various organ systems, including the kidney. Renal complications have rarely been reported compared with other irAEs and mostly consist of acute interstitial nephritis. Only rare cases of ICPI-related glomerulonephritis have been described. Herein, we report the case of an adult patient treated with pembrolizumab (anti-PD-1) for squamous cell carcinoma (SCC), who developed infectious enterocolitis, and ANCA-related with diffuse necrotizing crescentic glomerulonephritis, both conditions potentially linked to treatment with pembrolizumab.

Original languageEnglish (US)
Pages (from-to)801-804
Number of pages4
JournalVirchows Archiv
Issue number4
StatePublished - Apr 2021


  • ANCA
  • Crescentic glomerulonephritis
  • Immune checkpoint inhibitor
  • Immune-related adverse events
  • PD-1
  • Pembrolizumab

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab'. Together they form a unique fingerprint.

Cite this